September 19th 2024
"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP.
September 16th 2024
Role of PSMA PET Imaging in mCRPC
Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.
Patient Case #2: Choosing Optimal Therapy in mCRPC
Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.
The continuum of care in urologic oncology
November 26th 2021"The explosion in the number of therapies in this particular disease segment, especially those that have been deemed BCG unresponsive, seems very reminiscent to that witnessed in the mCRPC space a decade ago," writes Raoul S. Concepcion, MD, FACS.
Treatment options for high-volume mCNPC
Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.
Role of conventional imaging vs PSMA-PET in mCNPC
A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.
Perioperative yoga improves QOL in patients with new diagnosis of prostate cancer
November 23rd 2021“Yoga improved quality of life in men compared to the standard of care, specifically on the fatigue scale, meaning they were less tired; on sexual function; and on their functional, physical and social wellbeing,” said Dharam Kaushik, MD.
How plant-based diets are lowering the risk of aggressive prostate cancer
November 22nd 2021“I believe that at every stage, it's very important that we focus on healthful lifestyle behaviors because we can improve [urologic patients’] overall survival and their cardiovascular health,” says Stacy Loeb, MD, PhD, MSc.
Patient Case #1: Treatment Selection in mCNPC
Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.
Polling Questions: Advanced Prostate Cancer
Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.
The ENGAGEMENT study and virtual genetics board
November 11th 2021“There really are many considerations regarding germline testing, results interpretation, implications for treatment or screening, and the familial hereditary implications of this whole field. Because of that, understanding the role of genetic counseling is critical, and also understanding the interplay with various somatic testing approaches is also really important,” says Veda N. Giri, MD.
Study investigates management strategies for intermediate to high-risk prostate cancer
November 11th 2021“We [at GenesisCare] would be really interested in looking at strategies to identify men that we think are aggressive but localized and offer them a chance to do a shorter course hormonal therapy, which is going to substantially improve quality of life without losing on the efficacy end,” says Bridget F. Koontz, MD.
Researchers investigate association between gut microbiome and aggressive prostate cancer
November 8th 2021“There's been a lot of evidence over the past few years that there's certainly a…correlation between dietary intake and risk of prostate cancer, [but] there's really not a whole lot of data on risk of development of lethal prostate cancer,” says Nima Sharifi, MD.
Dr. Koontz on study of dose-escalated RT plus androgen suppression in prostate cancer
November 6th 2021“The RTOG-0815 study [of dose-escalated RT plus androgen suppression] has provided...data to have an intelligent conversation with our patients and provide them numbers so that they know what to expect,” says Bridget F. Koontz, MD.
Oral immune activator BXCL701 advances in pipeline for neuroendocrine prostate cancer
November 2nd 2021A phase 2a efficacy analysis has been launched exploring the combination of the novel oral immune activator BXCL701 and pembrolizumab in prostate cancer patients with de novo or treatment-emergent small cell neuroendocrine carcinoma.
Dose-escalated RT plus androgen suppression yields mixed outcomes in prostate cancer
October 28th 2021“Patients with intermediate-risk prostate cancer we know benefit from both escalation of radiotherapy dose as well as from the addition of androgen suppression. Technically, we still don’t know if we need both,” said Daniel Krauss, MD.